Asset Details
Do you wish to reserve the book?
Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
Do you wish to request the book?
Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
2021
Overview
This retrospective study aimed to identify predictors for the development of palbociclib-induced neutropenia. This study retrospectively analysed 78 breast cancer patients who had received palbociclib at our hospital between January 2018 and May 2020. For the regression analysis of factors associated with palbociclib-induced neutropenia, variables were extracted manually from medical charts. The level of palbociclib-induced neutropenia was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of neutropenia. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of
P
< 0.05 (2-tailed) were considered significant. Significant factors identified included concomitant use of statin (odds ratio [OR] = 0.104, 95% confidence interval [CI] = 0.018–0.598;
P
= 0.011) and body mass index (BMI) (OR = 1.118, 95% CI = 1.007–1.241;
P
= 0.037). ROC analysis revealed that neutropenia (grade 4) was more likely to occur with a BMI ≥ 22.3 kg/m
2
. In conclusion, no concomitant use of statins and high BMI were identified as significant predictors for the development of palbociclib-induced neutropenia.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/4028
/ 692/499
/ 692/700
/ Adult
/ Aged
/ Antineoplastic Agents - adverse effects
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Neutropenia - chemically induced
/ Patients
/ Piperazines - adverse effects
/ Science
/ Statins
